İzole Abducens Paralizisi ve Akut Koroner Sendrom ile prezente olan Paraganglioma olgusu

Year 2020, Volume: 3 Issue: 3, 124 - 128, 31.12.2020

Ahmet Çayakar

https://doi.org/10.33713/egetbd.589428

Abstract

Paragangliomalar, adrenal bez
dışındaki otonomik sinir sisteminin ganglion zincir kromaffin hücrelerinden
köken alırlar ve katekolamin salgılayan tümörlerin %10-15'ini oluştururlar. Yetişkinlerde
en sık dördüncü ve beşinci dekadda gözlenirler. Klinikte hipertansiyon,
çarpıntı ve terleme ataklarının eşlik ettiği baş ağrısına vurgu yapılmaktadır.
Bununla birlikte, hastaların %5-15'i normotensif olup ortostatik hipotansiyon
atakları dahi yaşayabilir. Kardiyovasküler komplikasyonlar arasında miyokardit,
kardiyomiyopati, atriyal veya ventriküler aritmiler, akut koroner sendrom
bulunmaktadır. Özellikle hipovolemi varlığında vasküler ton kaybı eklenmesiyle
birlikte şok tablosu gözlenebilir. Nörolojik bulgular olarak ise mental durum
değişiklikleri, hipertansif ensefalopati ve inme sıralanabilir. Bu makalemizde
iç hastalıkları polikliniğine başvurusu sonrası paraganglioma tanısı konulan
hasta sunulmaya çalışılmıştır.

Keywords

Paraganglioma, Akut koroner sendrom, İzole Abducens paralizisi

A case of paraganglioma presenting with isolated Abducens Paralysis and Acute Coronary Syndrome

Abstract

Paragangliomas originate from
ganglion chain chromaffin cells of the autonomic nervous system other than the
adrenal gland and constitute 10-15% of catecholamine-secreting tumors. They are
most frequently observed in the fourth and fifth decade in adults. In the
clinic, headache associated with hypertension, palpitation and sweating attacks
is emphasized. However, 5-15% of patients are normotensive and may experience
orthostatic hypotension attacks. Cardiovascular complications include
myocarditis, cardiomyopathy, atrial or ventricular arrhythmias, and acute
coronary syndrome. Shocks may be observed with the addition of vascular tone
loss especially in the presence of hypovolemia. As neurological findings mental
status changes, hypertensive encephalopathy and stroke can be listed. In this
article, we present a patient who was diagnosed with paraganglioma after
admission to the internal medicine outpatient clinic.

Keywords

Paraganglioma, Acute coronary syndrome, Abducens paralysis

References

• Bolu E et al. Feokromasitoma ve Paraganglioma. Adrenal ve Gonadal Hastalıklar Kılavuzu, Adrenal ve Gonadal Hastalıklar Çalışma Grubu. Türkiye Endokrinoloji ve Metabolizma Derneği, 12. Baskı Mayıs 2018; pages 47-63
• Çetinkalp Ş. Endokrinoloji. Feokromasitoa 1. Baskı. Türkiye : Türkiye Klinikleri Inc 2017; pages 251-266
• Kantorovich V, Koch CA, Pacak K. Pheochromocytoma and Paraganglioma Emergencies. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-2015; Apr 12
• Petri BJ, Van Eijck CHJ, De Herder WW, Wagner A, De Krijger RR. Phaeochromocytomas and sympathetic paragangliomas, British Journal of Surgery 2009; 96: 1381-1392
• Plouin PF, Gimenez-Roqueplo AP. Pheochromocytomas and secreting paragangliomas. Orphanet Journal of Rare Diseases 2006; 1:49
• Erdoğan G. Adrenal Medulla ve Hastalıkları. Endokrinoloji Temel ve Klinik. 2. Baskı. Türkiye : MN Medikal & Nobel Inc 2005; pages 561-571
• Özgen G. Adrenal Medulla ve Hastalıkları Kavramları. Kabalak T(ed), Yılmaz C(ed), Tüzün M(ed). Endokrinoloji El Kitabı. 3. Baskı. Türkiye : İzmir Güven Kitabevi Inc 2004; pages 473-480
• Pavai Z, Orosz Z, Horvath E, Seres-Sturm L, Jung J. Immunohistochemical features of paragangliomas. J.Cell.Mol.Med. 2001; Vol 5, No 2, 311-316
• Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ et al. Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators. J Clin Endocrinol Metab, March 2011; 96(3):717-725
• Laird AM, Gauger PG, Doherty GM, Miller BS. Paraganglioma: not just an extra-adrenal pheochromocytoma Langenbecks Arch Surg 2012; 397:247-253
• Fitzgerald SC, Gingell Littlejohn M, Parnaby CN, Connell JM, O’Dwyer PJ. Abdominal Paragangliomas: Analysis of Surgeon’s Experience. WorldJournal ofEndocrine Surgery, May-August 2011; 3(2):55-58
• Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J. Rare Dis. 2007; 2:22
• Kaltsas G, Dimitriadis GK, Androulakis II, Grossman A. Paraneoplastic Syndromes related to Neuroendorine Tumours. Endotext [Internet]. MDText.com, Inc, 2017 Feb 16
• Eisenhofer G, Tischler AS, De Krijger RR. Diagnostic Tests and Biomarkers for Pheochromocytoma and Extra-adrenal Paraganglioma: From Routine Laboratory Methods to Disease Stratification Endocr Pathol 2012; 23:4-14
• Parenti G, Zampetti B, Rapizzi E, Ercolino T, Giach V, Mannelli M. Updated and New Perspectives on Diagnosis, Prognosis, and Therapy of Malignant Pheochromocytoma/ Paraganglioma Journal of Oncology Volume 2012; 10 pages
• Ayala-Ramirez M, Palmer JL, Hoffman MC, de la Cruz M, Moon BS, Waguespack SG, Habra MA, Jimenez C: Bone Metastases and Skeletal-Related Events in Patients with Malignant Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab 2013
• Corssmit EP, Romijn JA. Management of endocrine disease : Clinical management of paragangliomas. European Journal of Endocrinology 2014; 171, R231–R243
• Jimenez C, Rohren E, Habra MA, Rich T, Jimenez P, Ayala Ramirez M and Baudin E: Current and future treatments for malignant pheochromocytoma and sympathetic paragan¬glioma. Curr Oncol Rep 2013; 15: 356-371